(18)F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab

Dostarlimab is an immune checkpoint inhibitor (ICI) targeting the Programmed-Death-1 (PD-1) co-receptor, recently approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) as a novel therapy for recurrent or advanced endometrial cancer. We report the case of a 64-yea...

Descripción completa

Detalles Bibliográficos
Autores principales: Seban, Romain-David, Donnadieu, Anne, Journo, Gabrielle, Bidard, Francois-Clement, Richard, Capucine, Rouzier, Roman, Champion, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Interesting Images
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391233/
https://www.ncbi.nlm.nih.gov/pubmed/34441288
http://dx.doi.org/10.3390/diagnostics11081353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391233/
https://www.ncbi.nlm.nih.gov/pubmed/34441288
http://dx.doi.org/10.3390/diagnostics11081353

Ejemplares similares